Hanmi's 10 drugs break W10 billion barrier in 2007

Hanmi Pharm says its 10 flagship products exceeded 10 billion won in sales last year, up two products from 2006.

By sales, Amodipin (amodipine camsylate) topped the list with 55.5 billion won, followed by Medilac (lactic bacterial culture+) with 18.9 billion won, Carnitil with 15.5 billion won, Clari (clarithromycin) with 14.8 billion won, Slimmer (sibutramine mesylate) with 14.5 won, Triaxo...